Steve Paul acknowledged that gene therapy, despite its progress, is still in its early days. So is his company, Voyager Therapeutics—which is 14 months old yet is now poised for an IPO, as we wrote yesterday.
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars